| symbol |
SBOT |
|---|
| 会社名 | Stellar Biotechnologies Inc （ステラ―・バイオテクノロジ―ズ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Stellar Biotechnologies Inc. is a biotechnology company. The Company is engaged in the aquaculture research and development manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company's core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company's Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing and Custom KLH formulations adjuvants conjugations and fill finishes for preclinical research and drug development applications. ステラ―・バイオテクノロジ―ズは米国のバイオ医薬品企業。キ―ホ―ル・リンペット・ヘモシアニン(KLH)たんぱく質の開発・商業化に従事。主に同社ブランドである「ステラ―KLH」の製造と供給を行う。臨床前に使用、臨床時に応用、また特定のKLHベ―スの試験管内の診断キット用など、各種等級と製剤を提供する。本社はカリフォルニア州。 Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA.
|
|---|
| 本社所在地 | 332 E. Scott Street Port Hueneme CA 93041 USA |
|---|
| 代表者氏名 | Frank R. Oakes フランクR.オーケス |
|---|
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
|---|
| 電話番号 | +1 805-488-2800 |
|---|
| 設立年月日 | 39234 |
|---|
| 市場名 | NASDAQ Small Cap |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 28人 |
|---|
| url | www.stellarbiotech.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/sbot |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -5.07458 |
|---|
| 終値（lastsale） | 1.37 |
|---|
| 時価総額（marketcap） | 7303079.55 |
|---|
| 時価総額 | 時価総額（百万ドル） 7.14316 |
|---|
| 売上高 | 売上高（百万ドル） 0.16047 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） -4.14098 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -5.13089 |
|---|
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Stellar Biotechnologies Inc revenues decreased 30% to $158K. Net loss increased 3% to $3.9M. Revenues reflect Revenue from Contract with Customer decrease from $50K to $0K Product sales decrease of 10% to $158K. Higher net loss reflects Research and development increase of 20% to $1.6M (expense) Foreign exchange gain (loss) decrease from $22K (income) to $48K (expense). |
|---|